ALFA Finder| Management target | EBITDA Margin 20.0% FY27 |
|---|
| Revenue growth | 11.6% YoY revenue growth led by hospital and MetLife segments. |
|---|---|
| Margins | Consolidated EBITDA margins down to 14.5% due to expansion costs. |
| Demand visibility | Strong traction in orthopedic implants and international medical tourism. |
| Management confidence | Balanced; optimistic on MetLife scaling and hospital margin recovery. |
Growth
Revenue grew 11.6% YoY to ₹338.6 Cr; PAT grew 36% to ₹10.5 Cr.
Outlook
Management guides for 20% EBITDA margins for the full FY27 year.
Risks
Hospital margins compressed 320bps; heavy reliance on government schemes potentially lengthening receivables cycles.
Last quarter's promises, checked
Delivered
- Guided MedTech EBITDA breakeven → delivered ₹3.7 Cr positive EBITDA (= BEAT)
- Guided 15% long-term hospital CAGR → delivered 11.6% revenue growth (= PARTIAL)
- Guided new tax regime benefit → delivered PAT growth of 36% (= BEAT)
Partly delivered
- Guided inventory reduction → delivered efficiency improvements but net debt rose to ₹463 Cr (= PARTIAL)
Missed
- Guided hospital margin stability → delivered 320bps margin compression (= MISS)
- Guided reduction in government business → delivered 32% payor mix (= MISS)
Earnings Call Transcript filed with BSE, NSE: SHALBY. Summary written with AI assistance from the document.
Shalby Ltd: key numbers
- Share price
- ₹126.99
- Market cap
- ₹1,372 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 35.0×Sector 54.5×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Other Announcement
Shalby Limited disclosed under Regulation 30(5) that the board authorised KMP personnel for materiality determination. Mr. Tushar Shah's designation was revised after his appointment as Executive Director.
Shalby Earnings Call Transcript: Key Takeaways
Consolidated revenue rose 9.8%, but EBITDA grew only 0.8% and margin fell 130 bps to 14.6%. PAT was flat at ₹7.9 Cr. Standalone hospitals carry profit while subsidiaries drag. Management deflected on Mumbai, MedTech expansion and POSO revenue.
Shalby Investor Presentation: Key Takeaways
Consolidated Q2 FY27 revenue ₹3,182mn (+9.8% YoY), EBITDA flat at ₹464mn, margin 14.6%, PAT ₹79mn (+8.3%). Standalone PAT +19%; growth driven by International and occupancy.
Shalby Annual General Meeting
Shalby Ltd seeks shareholder approval via postal ballot to appoint Shanay Vikram Shah and Tushar Shah as directors. E-voting runs November 5 to December 4, 2026.
Shalby Management Change
Shalby Limited appointed Mr. Tushar Shah as Executive Director for five years, effective November 3, 2026, subject to shareholder approval. The change is a senior management appointment.
- Execution
- 5 years from November 3, 2026
Shalby Q2 FY27 Results: Net Profit ₹7.9 Cr, Up 8.2% YoY
Shalby Ltd reported revenue from operations of ₹313.2 Cr (+9.7% YoY) and net profit of ₹7.9 Cr (+8.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.9 Cr · +8.2% YoY